TABLE 5

Summary of drug interaction predictions using inactivation parameter estimates from various sources

Predictions were performed using Simcyp version 9.10.

Diltiazem SR-Midazolam p.o.Verapamil SR-Midazolam p.o.Clarithromycin-Midazolam p.o.Erythromycin-Midazolam p.o.
MerckaZhaobSimcypcXudMerckaSimcypbXudMerckaMayheweXudYamanofSimcypZhaobXudMercka
HLM (mg/ml)10.2<0.511<0.5110.215N.A.0.211
Dilution1:101:10N.A.1:201:10N.A.1:201:101:101:201:20N.A.1:101:201:10
Substrate conc. (μM)TESTMDZTESTMDZTESTTESTMDZTESTMDZMDZMDZN.A.MDZMDZTEST
(250)(100)(50)(20)(250)(50)(20)(250)(200)(20)(10)(100)(20)(250)
fu, mic0.71g0.90.90.8210.373g0.770.590.804g0.954g0.320.530.9720.9250.8710.804g
kinact (h−1)1.380.724.21.143.485.33.181.84.33.783.931.494.321.022.16
KI (μM)1.90.53h3.30.674.41.83.54.565.4915.7281.813.415.21.73.5
Predicted AUC Ratioi3.0 ± 1.63.5 ± 1.93.7 ± 2.14.2 ± 2.52.9 ± 2.03.9 ± 3.12.5 ± 1.56.9 ± 4.79.1 ± 6.99.1 ± 7.04.03.93.811.512.9
(1.4 − 6.3)(1.5 − 7.4)(1.6 − 8.0)(1.6 − 9.4)(1.3 − 6.9)(1.4 − 10)(1.3 −5.5)(1.8 − 17)(2.0 − 22)(2.0 − 23)
Observed AUC ratioj3.5 ± 0.94.1 ± 2.48.0 ± 4.44.4k
(1.8 − 4.4)(1.7 − 11.7)(3.8 − 14.8)
Study referencelWang et al., 2005Wang et al., 2004aOlkkola et al., 1993
  • HLM, human liver microsomes; TEST, testosterone; MDZ, midazolam; N.A., not available.

  • a Merck unpublished data;

  • b Data from Zhao et al., 2005;

  • c Data from Yeo and Yeo, 2001;

  • d Data from Xu et al., 2009;

  • e Data from Mayhew et al., 2000;

  • f Data from Yamano et al., 2001;

  • g Simcyp-predicted;

  • h Back-calculated by assuming free fraction in microsomal incubation;

  • i Mean ± S.D. (5th–95th percentile);

  • j Mean ± S.D. (range);

  • k S.D. and range were not available;

  • l Friedman EJ, Fraser IP, Wang YH, Bergman A, Li CC, Larson P, Chodakewitz J, Wagner JA, and Stoch SA, manuscript submitted for publication.